期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
沙利度胺联合CHOP方案治疗外周T细胞淋巴瘤的效果 被引量:1
1
作者 段现良 马丛丛 化静 《中国实用医刊》 2020年第4期94-97,共4页
目的探讨沙利度胺联合CHOP方案(环磷酰胺+表柔比星+长春新碱+泼尼松)治疗外周T细胞淋巴瘤的临床效果。方法选取2017年1月至2019年1月于聊城市人民医院接受治疗的外周T细胞淋巴瘤患者72例,按随机数字表法分为观察组(36例)与对照组(36例)... 目的探讨沙利度胺联合CHOP方案(环磷酰胺+表柔比星+长春新碱+泼尼松)治疗外周T细胞淋巴瘤的临床效果。方法选取2017年1月至2019年1月于聊城市人民医院接受治疗的外周T细胞淋巴瘤患者72例,按随机数字表法分为观察组(36例)与对照组(36例)。对照组采用CHOP方案治疗,观察组则在对照组基础上联合沙利度胺治疗。3周为一疗程,两组均连续治疗8个疗程。比较两组临床疗效与治疗前后的精氨酸酶1(Arg-1)、血管内皮生长因子(VEGF)、诱生型一氧化氮合酶(iNOS)水平及治疗期间的不良反应(胃肠道反应、肝损伤、骨髓抑制、神经毒性、脱发、皮疹)情况。结果治疗后,观察组总有效率(86.11%)高于对照组(63.89%),差异有统计学意义(P<0.05);治疗后,观察组Arg-1、VEGF、iNOS水平[(12.38±2.50)ng/ml、(20.11±10.02)pg/ml、(14.96±3.72)U/ml]低于对照组[(14.29±2.40)ng/ml、(32.72±10.43)pg/ml、(16.77±3.80)U/ml],差异有统计学意义(P<0.05);治疗期间,两组各项不良反应的发生率比较,差异未见统计学意义(P>0.05)。结论沙利度胺联合CHOP方案治疗外周T细胞淋巴瘤的临床效果显著,能有效降低Arg-1、VEGF、iNOS水平,且不会增加不良反应发生率。 展开更多
关键词 外周t细胞淋巴癌 CHOP方案 沙利度胺
原文传递
T-regulatory lymphocytes in peripheral blood of gastric and colorectal cancer patients 被引量:5
2
作者 Antoni M Szczepanik Maciej Siedlar +4 位作者 Marek Sierzega Dominika Goroszeniuk Karolina Bukowska-Strakova Antoni Czupryna Jan Kulig 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第3期343-348,共6页
AIM: To assess the absolute number of T-regulatory cells (Tregs; CD4+CD25+Foxp3+) in the peripheral blood of gastric and colorectal cancer patients. METHODS: We enrolled 70 cancer patients (33 gastric cancer, 37 color... AIM: To assess the absolute number of T-regulatory cells (Tregs; CD4+CD25+Foxp3+) in the peripheral blood of gastric and colorectal cancer patients. METHODS: We enrolled 70 cancer patients (33 gastric cancer, 37 colorectal cancer) and 17 healthy volunteers. The CD3+CD4+ lymphocytes and CD4+CD25+Foxp3+ Tregs in the peripheral blood were analyzed with flow cytometry. The absolute numbers of Tregs were calculated based on the CD4+CD25+Foxp3+ cells percent-age of CD3+CD4+ cells and the absolute numbers of CD3+CD4+ cells per microliter. RESULTS: The mean number of CD4+CD25+Foxp3+ cells per microliter in colorectal cancer patients was 15.7 (SD: 21.8), for gastric cancer patients 12.2 (SD: 14.3), and for controls 17.5 (SD: 11.4). The absolute number of Tregs was significantly lower in gastric cancer patients than in controls (P = 0.026). There was no statistically significant difference for gastric vs colorectal cancer or colorectal cancer vs controls. The absolute number of Tregs was also significantly depressed in N+ vs Ncancer patients [22.0 (27.7) vs 10.1 (9.0), P = 0.013], and in the subgroup of gastric cancer patients [30.3 (27.6) vs 9.6 (8.0), P = 0.003]. No statistical difference was observed in the proportion of Tregs in the CD4+ population between the groups. CONCLUSION: The absolute number of Tregs in peripheral blood of gastric cancer but not colorectal cancer patients was significantly decreased in comparison with that in healthy controls. 展开更多
关键词 CD4+CD25+Foxp3+ cells t regulatory cells Peripheral blood Gastric cancer Colorectal cancer
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部